Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ChronosAntibiotics

Financiado

Cerrado

Exploring the bacterial cell cycle to re sensitize antibiotic resistant bacteria

Over the next 35 years, antibiotic resistant bacteria are expected to kill more than 300 million people. The need to find alternative strategies for antimicrobial therapies remains a global challenge with several bottlenecks in th... ver más

31/03/2024

UNL

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UNIVERSIDADE NOVA DE LISBOA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-03-31

ERC-2017-COG: ERC Consolidator Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNL

2.53M€ | Lider

HARINERA VILAFRANQUINA

1.21M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MissingLinks Finding the missing links in the bacterial cell cycle 3M€ Cerrado

BIO2014-51806-R COMBATIENDO LOS DETERMINANTES GENETICOS DE PAN-RESISTENCIA A... 212K€ Cerrado

NONANTIRES Non genetic mechanisms of intrinsic antimicrobial resistance 50K€ Cerrado

PID2021-122705OB-I00 REDIRECCIONANDO EL DESCUBRIMIENTO DE ANTIMICROBIALES Y UTILI... 169K€ Cerrado

IN-ARMOR THERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO... 6M€ Cerrado

TROCAR Translational Research on Combating Antimicrobial Resistance 4M€ Cerrado

Duración del proyecto: 73 meses Fecha Inicio: 2018-02-18
Fecha Fin: 2024-03-31

Líder del proyecto

UNIVERSIDADE NOVA DE LISBOA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Over the next 35 years, antibiotic resistant bacteria are expected to kill more than 300 million people. The need to find alternative strategies for antimicrobial therapies remains a global challenge with several bottlenecks in the antibiotic discovery process. Using Staphylococcus aureus, the most common multidrug-resistant bacterium in the European Union and an excellent model organism for cell division in cocci, we propose: (i) to find new pathways to re-sensitize resistant bacteria. Bacteria undergo major morphology changes during the cell cycle. We hypothesize that these changes generate windows of opportunity during which bacteria are more susceptible or more tolerant to the action of antibiotics. We will identify key regulators of the cell cycle in order to manipulate the duration of windows of opportunity for the action of existing antibiotics. (ii) to develop new fluorescence-based reporters for whole-cell screenings of antimicrobial compounds with new modes of action, including compounds that arrest or delay the cell cycle; compounds that target non-essential pathways that are required for expression of resistance against existing antibiotics and therefore can be used as synergistic drugs for combination therapies; compounds that inhibit the production of virulence factors and compounds that revert persister states that are phenotypically resistant to antibiotics. (iii) to unravel new modes of action of antibiotics by using the constructed reporter strains as powerful tools to learn how antibiotics act at the single cell level. Over the past years, my group has become expert on the biology of S. aureus, has constructed powerful biological tools to study cell division and synthesis of the cell surface and has studied mechanisms of action of various antimicrobial compounds. We are therefore in a privileged position to quickly unravel the function of new players in the bacterial cell cycle and simultaneously contribute to accelerate antibiotic discovery.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores